A3 Adenosine and P2X7 Purinergic Receptors as New Targets for an Innovative Pharmacological Therapy of Malignant Pleural Mesothelioma
Human malignant pleural mesothelioma (MPM) is a rare, but aggressive tumor of the serosal cavities whose 5-year survival rate is 15%. At present, there are no effective therapies for MPM. Although recent findings suggest that A3 adenosine (A3AR) and P2X7 (P2X7R) receptors can be employed as antitumo...
Main Authors: | Fabrizio Vincenzi, John Charles Rotondo, Silvia Pasquini, Francesco Di Virgilio, Katia Varani, Mauro Tognon |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-10-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.679285/full |
Similar Items
-
Adenosine Deaminase Inhibitor EHNA Exhibits a Potent Anticancer Effect Against Malignant Pleural Mesothelioma
by: Yasuhiro Nakajima, et al.
Published: (2015-01-01) -
Tumour associated lymphocytes in the pleural effusions of patients with mesothelioma express high levels of inhibitory receptors
by: Jonathan Chee, et al.
Published: (2018-12-01) -
Malignant pleural mesothelioma
by: Rao Sukhesh
Published: (2009-01-01) -
Targeting Adenosine Receptors: A Potential Pharmacological Avenue for Acute and Chronic Pain
by: Fabrizio Vincenzi, et al.
Published: (2020-11-01) -
Management of Pleural Effusion Secondary to Malignant Mesothelioma
by: Valeria Musso, et al.
Published: (2021-09-01)